Different clinical guidelines, common goal: To reduce COVID-19 mortality

Sun, Liqin1,2; Liu, Jiaye3; Zhao, Fang1,2; Chen, Jun4; Lu, Hongzhou1,2,5

2023

10.5582/bst.2023.01009

BioScience Trends   影响因子和分区

1881-7815

1881-7823

The tendency of the Omicron variant to rapidly became the dominant SARS-CoV-2 strain and its weaker virulence than other strains worldwide has prompted many countries to adjust their public health strategies. This work summarizes all appropriate clinical interventions to reduce the public health burden caused by COVID-19 according to guidelines from the World Health Organization and 10 countries, i.e., the United States of America (USA), India, France, Germany, Brazil, South Korea, Japan, Italy, the United Kingdom (UK), and China. Five stages of COVID-19 were identified: asymptomatic infection and mild, moderate, severe, and critical illness. Most guidelines recommend antivirals starting with mild cases for those from Germany and India. Since more drugs are being developed and are becoming available to COVID-19 patients, guidelines are increasingly being updated with new pharmacological intervention strategies. Thus, a global view needs to be adopted to provide helpful options and precise treatment strategies during the lasting fight against the COVID-19 pandemic.

Covid-19 SARS-COV-2 guidelines emerging infectious disease public health

SCI

英语

第一 ; 通讯

National Natural Science Foundation of China[92169119] ; Shenzhen Municipal Science and Technology Innovation Committee[JCYJ20220531102202005]

Life Sciences & Biomedicine - Other Topics

Biology

WOS:000921615000001

IRCA-BSSA

Web of Science

1.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Guangdong, Peoples R China
2.Southern Univ Sci & Technol, Hosp Affiliated 2, Shenzhen, Guangdong, Peoples R China
3.Shenzhen Univ, Sch Publ Hlth, Hlth Sci Ctr, Shenzhen, Guangdong, Peoples R China
4.Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect Dis & Immunol, Shanghai, Peoples R China
5.Shenzhen Third Peoples Hosp, Natl Clin Res Ctr Infect Dis, Dept Infect Dis, Shenzhen 518112, Guangdong, Peoples R China

Sun, Liqin,Liu, Jiaye,Zhao, Fang,et al. Different clinical guidelines, common goal: To reduce COVID-19 mortality[J]. BioScience Trends,2023.

Sun, Liqin,Liu, Jiaye,Zhao, Fang,Chen, Jun,&Lu, Hongzhou.(2023).Different clinical guidelines, common goal: To reduce COVID-19 mortality.BioScience Trends.

Sun, Liqin,et al."Different clinical guidelines, common goal: To reduce COVID-19 mortality".BioScience Trends (2023).